卵巢癌免疫治疗与个性化医学。
Ovarian Cancer Immunotherapy and Personalized Medicine.
机构信息
Department of Medicine, University of Toledo, Toledo, OH 43614, USA.
Gradalis, Inc., Carrollton, TX 75006, USA.
出版信息
Int J Mol Sci. 2021 Jun 18;22(12):6532. doi: 10.3390/ijms22126532.
Abstract
Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.
摘要
卵巢癌对免疫疗法的反应有限；然而，根据肿瘤生物标志物进行分层，评估对敏感/耐药靶向治疗亚群，可能会提高免疫疗法反应的预测性。这些标志物包括肿瘤突变负担、PD-L1、肿瘤浸润淋巴细胞、同源重组缺陷和新抗原肿瘤内异质性。卵巢癌治疗的未来方向包括利用这些生物标志物来选择理想的候选者。本文综述了免疫疗法在卵巢癌中的作用，以及涉及肿瘤生物标志物的新疗法和研究设计，这些标志物增加了卵巢癌免疫疗法成功的可能性。
相似文献
1
Ovarian Cancer Immunotherapy and Personalized Medicine.卵巢癌免疫治疗与个性化医学。
Int J Mol Sci. 2021 Jun 18;22(12):6532. doi: 10.3390/ijms22126532.
2
The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.癌症睾丸抗原在卵巢癌中的潜在价值：预后标志物和免疫治疗靶点。
Immun Inflamm Dis. 2024 Jun;12(6):e1284. doi: 10.1002/iid3.1284.
3
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.个性化肿瘤学与免疫学相遇：精准免疫治疗之路。
Cancer Discov. 2016 Jul;6(7):703-13. doi: 10.1158/2159-8290.CD-16-0146. Epub 2016 Apr 22.
4
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.肿瘤内注射负载新抗原肽的树突状细胞疫苗可在 1 例化疗耐药性伴恶性腹水的卵巢癌患者中诱导出针对表位的 T 细胞反应和临床疗效。
Immunol Invest. 2021 Jul;50(5):562-579. doi: 10.1080/08820139.2020.1778721. Epub 2020 Jul 13.
5
Tumor antigens in glioma.脑胶质瘤中的肿瘤抗原。
Semin Immunol. 2020 Feb;47:101385. doi: 10.1016/j.smim.2020.101385. Epub 2020 Feb 6.
6
Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond.利用肿瘤免疫基因组学：卵巢癌及其他癌症中的肿瘤新抗原
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189017. doi: 10.1016/j.bbcan.2023.189017. Epub 2023 Nov 5.
7
Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.用于基于树突状细胞的卵巢癌免疫治疗的新型靶抗原。
Expert Rev Anticancer Ther. 2002 Feb;2(1):97-105. doi: 10.1586/14737140.2.1.97.
8
Cancer neoantigen: Boosting immunotherapy.癌症新生抗原：增强免疫疗法。
Biomed Pharmacother. 2020 Nov;131:110640. doi: 10.1016/j.biopha.2020.110640. Epub 2020 Aug 21.
9
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.卵巢癌中微卫星不稳定性、免疫细胞浸润与免疫检查点分子表达的关系：未来的免疫治疗策略。
Int J Mol Sci. 2019 Oct 16;20(20):5129. doi: 10.3390/ijms20205129.
10
Precision targeted therapy of ovarian cancer.卵巢癌的精准靶向治疗
J Control Release. 2016 Dec 10;243:250-268. doi: 10.1016/j.jconrel.2016.10.014. Epub 2016 Oct 14.
引用本文的文献
1
The SPINK Protein Family in Cancer: Emerging Roles in Tumor Progression, Therapeutic Resistance, and Precision Oncology.癌症中的丝氨酸蛋白酶抑制剂Kazal型相关肽（SPINK）蛋白家族：在肿瘤进展、治疗抗性和精准肿瘤学中的新作用
Pharmaceuticals (Basel). 2025 Aug 13;18(8):1194. doi: 10.3390/ph18081194.
2
Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.卵巢肿瘤免疫肽组学的蛋白质基因组学方法鉴定出共享的肽疫苗候选物。
NPJ Vaccines. 2025 Aug 16;10(1):195. doi: 10.1038/s41541-025-01234-6.
3
Therapeutic landscape of ovarian cancer: recent advances and emerging therapies.卵巢癌的治疗格局：最新进展与新兴疗法
Biomark Res. 2025 Aug 12;13(1):103. doi: 10.1186/s40364-025-00818-7.
4
Integrative approach for enhanced ovarian cancer diagnosis: cytology and biomarkers.用于增强卵巢癌诊断的综合方法：细胞学与生物标志物
Discov Oncol. 2025 Aug 10;16(1):1519. doi: 10.1007/s12672-025-03231-6.
5
Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis.基于免疫疗法的卵巢癌治疗的全球研究趋势：文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
6
Visual analysis of ovarian cancer immunotherapy: a bibliometric analysis from 2010 to 2025.卵巢癌免疫治疗的可视化分析：2010年至2025年的文献计量分析
Front Med (Lausanne). 2025 Jul 11;12:1573512. doi: 10.3389/fmed.2025.1573512. eCollection 2025.
7
Association of Tissue Expression of LAG-3 and TIM-3 with Clinical Features in Ovarian Cancer.卵巢癌中LAG-3和TIM-3的组织表达与临床特征的关联
Int J Mol Sci. 2025 Jun 22;26(13):5996. doi: 10.3390/ijms26135996.
8
Modulating ovarian cancer progression through FDX1-driven autophagy.通过FDX1驱动的自噬调节卵巢癌进展。
NPJ Precis Oncol. 2025 Jul 8;9(1):230. doi: 10.1038/s41698-025-00994-7.
9
Integrated multi-omics analysis reveals the immunotherapeutic significance of tumor cells with high FN1 expression in ovarian cancer.整合多组学分析揭示了 FN1 高表达肿瘤细胞在卵巢癌中的免疫治疗意义。
Front Mol Biosci. 2025 Jun 19;12:1611964. doi: 10.3389/fmolb.2025.1611964. eCollection 2025.
10
FAM111B Overexpression and Immune Cell Infiltration: Implications for Ovarian Cancer Immunotherapy.FAM111B过表达与免疫细胞浸润：对卵巢癌免疫治疗的意义
Biomedicines. 2025 May 24;13(6):1295. doi: 10.3390/biomedicines13061295.
本文引用的文献
1
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.帕博利珠单抗与化疗治疗微卫星高度不稳定或错配修复缺陷转移性结直肠癌（KEYNOTE-177）：一项随机、开放标签、III 期研究的最终分析。
Lancet Oncol. 2022 May;23(5):659-670. doi: 10.1016/S1470-2045(22)00197-8. Epub 2022 Apr 12.
2
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.基因座蛋白聚糖-T（ Vigil ）免疫疗法在同源重组修复（ HRP ）有效的卵巢癌中显示出临床获益。
Gynecol Oncol. 2021 Jun;161(3):676-680. doi: 10.1016/j.ygyno.2021.03.009. Epub 2021 Mar 11.
3
Mutation Status Impact on Autophagy and Immune Response: Unheralded Target.突变状态对自噬和免疫反应的影响：未被关注的靶点。
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Dec.
4
Current Ovarian Cancer Maintenance Strategies and Promising New Developments.当前卵巢癌维持治疗策略及有前景的新进展
J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406. eCollection 2021.
5
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance.关于晚期卵巢癌患者一线维持治疗中使用Vigil®进行2A期试验结果的长期随访
Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov.
6
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.注射用维迪西妥单抗（VEGF）联合化疗一线治疗晚期胃癌的随机、双盲、安慰剂对照、多中心的 III 期临床研究（RCG108）
Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
7
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.帕博利珠单抗治疗微卫星高度不稳定型晚期结直肠癌。
N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.
8
Association between tumor mutation burden and immune infiltration in ovarian cancer.卵巢癌中肿瘤突变负担与免疫浸润的相关性。
Int Immunopharmacol. 2020 Dec;89(Pt A):107126. doi: 10.1016/j.intimp.2020.107126. Epub 2020 Nov 11.
9
Tumor-infiltrating lymphocytes in the immunotherapy era.免疫治疗时代的肿瘤浸润淋巴细胞。
Cell Mol Immunol. 2021 Apr;18(4):842-859. doi: 10.1038/s41423-020-00565-9. Epub 2020 Nov 2.
10
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.肿瘤浸润淋巴细胞及其在皮肤黑色素瘤中的预后价值。
Front Immunol. 2020 Sep 10;11:2105. doi: 10.3389/fimmu.2020.02105. eCollection 2020.
Zotero 插件